Andrew Walding

Andrew Walding is a highly experienced medical scientist and the Global Safety Head (Executive Director) for Patient Safety in Oncology at AstraZeneca. With extensive end-to-end experience in drug discovery and development, they have successfully led Phase I-III studies and clinical submissions, exemplifying a patient-focused and innovative leadership style. Andrew's significant contributions include overseeing the Tagrisso programme and the launch of Project Patient Voice with the FDA. They currently concentrate on Late Phase Oncology Development, particularly in HR+ Breast Cancer, continually advocating for improvements in patient outcomes. Andrew holds a Bachelor of Science in Biochemistry and Genetics from the University of Nottingham and a distinction from the University of Manchester.